Crysvita® (burosumab-twza) Non-Oncology

Covers Crysvita (burosumab‑twza) for the FDA‑approved treatment of X‑linked hypophosphatemia (non‑oncology) in patients ≥6 months; other indications are excluded. Initial approval requires a baseline low serum phosphorus (before any XLH treatment) plus either low TmP/GFR or a PHEX pathogenic variant, adults must also have XLH signs/symptoms and have tried oral phosphate + calcitriol unless contraindicated, the drug must be prescribed by or in consultation with an endocrinologist/nephrologist, approvals are for 12 months with reauthorization requiring documented clinical benefit, and dosing is limited per label (pediatric/ adult regimens up to 90 mg).

""Crysvita is prescribed by or in consultation with an endocrinologist or nephrologist;" (documentation of prescribing clinician specialty or consultation)."

Sign up to see full coverage criteria, indications, and limitations.